Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BRAF V600E Metastatic NSCLC”

13 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 13 of 13 results

Testing effectiveness (Phase 2)Study completedNCT04452877
What this trial is testing

Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 40
Testing effectiveness (Phase 2)WithdrawnNCT02672358
What this trial is testing

Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC

Who this might be right for
Non-Small-Cell Lung Cancer
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)UnknownNCT03543306
What this trial is testing

Dabrafenib and Trametinib in Patients With Non-small Cell Lung Cancer Harboring V600E BRAF Mutation

Who this might be right for
CancerLung Cancer MetastaticBRAF V600E
Asan Medical Center 27
Not applicableStudy completedNCT05546905
What this trial is testing

A Study in Patients With BRAF V600E-mutant Metastatic Non-small Cell Lung Cancer (OCTOPUS)

Who this might be right for
Metastatic Non-small Cell Lung CancerBRAF V600 Mutation
Pierre Fabre Medicament 206
Testing effectiveness (Phase 2)Study completedNCT01336634
What this trial is testing

Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.

Who this might be right for
Cancer
Novartis Pharmaceuticals 177
Testing effectiveness (Phase 2)UnknownNCT05900219
What this trial is testing

Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical Study

Who this might be right for
Non-small-cell Lung Cancer
Shanghai Kechow Pharma, Inc. 75
Testing effectiveness (Phase 2)Active Not RecruitingNCT04526782
What this trial is testing

ENCOrafenib With Binimetinib in bRAF NSCLC

Who this might be right for
Non Small Cell Lung CancerBRAF V600E
Intergroupe Francophone de Cancerologie Thoracique 119
Testing effectiveness (Phase 2)Ended earlyNCT04585815
What this trial is testing

Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Pfizer 34
Testing effectiveness (Phase 2)Study completedNCT06208124
What this trial is testing

IMM-6-415 in RAS/RAF Mutant Solid Tumors

Who this might be right for
Advanced Solid Tumor (Phase 1)Pancreas AdenocarcinomaNon-small Cell Lung Cancer+1 more
Immuneering Corporation 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT05195632
What this trial is testing

Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Pierre Fabre Medicament 63
Early research (Phase 1)Study completedNCT05003622
What this trial is testing

Phase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid Tumors

Who this might be right for
BRAF V600E Unresectable or Metastatic MelanomaBRAF V600E Metastatic NSCLCMelanoma
Pierre Fabre Medicament 3
Testing effectiveness (Phase 2)Looking for participantsNCT05786924
What this trial is testing

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Who this might be right for
Non-small Cell Lung CancerHistiocytic NeoplasmHistiocytosis+29 more
Institut de Recherches Internationales Servier 554
Testing effectiveness (Phase 2)Study completedNCT03915951
What this trial is testing

An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Pfizer 98